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Asthma is one of the most common chronic diseases of
childhood and is the most common cause of school absen-
teeism due to chronic conditions. The objective of this
study is to estimate direct and indirect costs of asthma in
school-age children.
Methods
Using data from the 1996 Medical Expenditure Panel
Survey, we estimated direct medical costs and school
absence days among school-age children who had treat-
ment for asthma during 1996. We estimated indirect costs
as costs of lost productivity arising from parents’ loss of
time from work and lifetime earnings lost due to prema-
ture death of children from asthma. All costs were calcu-
lated in 2003 dollars. 
Results
In 1996, an estimated 2.52 million children aged five to
17 years received treatment for asthma. Direct medical
expenditure was $1009.8 million ($401 per child with asth-
ma), including payments for prescribed medicine, hospital
inpatient stay, hospital outpatient care, emergency room
visits, and office-based visits. Children with treated asth-
ma had a total of 14.5 million school absence days; asthma
accounts for 6.3 million school absence days (2.48 days per
child with asthma). Parents’ loss of productivity from asth-
ma-related school absence days was $719.1 million ($285
per child with asthma). A total of 211 school-age children
died of asthma during 1996, accounting for $264.7 million
lifetime earnings lost ($105 per child with asthma). Total
economic impact of asthma in school-age children was
$1993.6 million ($791 per child with asthma).
Conclusion
The economic impact of asthma on school-age children,
families, and society is immense, and more public health
efforts to better control asthma in children are needed.
Introduction
One of the most common chronic disorders in children
and adolescents (1), asthma represents a major public
health problem of increasing concern in the United States.
Between 1980 and 1996, the prevalence of asthma
increased by an average of 4.3% per year, from 3.6% to
6.2% among children aged from birth to seven years (2).
Since then, asthma prevalence appears to be stable, and in
2001, more than 5 million children aged five to 17 in the
United States were reported to have a current diagnosis of
asthma (3). Previously published reports (4-8) strongly
suggest that asthma not only increases health care use
and costs but also places a large burden on affected chil-
dren and their families. Children with asthma miss out on
school, sports, and other childhood activities. Parents or
caregivers of children with asthma are affected by missed
workdays and decreased job productivity.
In 1992, Weiss et al (4) conducted a study of the asthma-
related costs in the U.S. population. They derived 
estimates of direct medical costs and indirect costs of pro-
ductivity loss (in 1985 dollars) using data from national
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surveys, including the National Health Interview Survey
(NHIS), the National Hospital Discharge Survey, the
National Ambulatory Medical Care Survey, and others.
Direct medical expenditures were estimated to be $465
million for children with asthma aged from birth to 17
years, and indirect costs (value of parents’ or caregivers’
productivity loss associated with school absence days
[SADs]) were estimated to be $726 million among school-
age children. Because none of the national surveys collects
diagnostic and expenditure data, only national expendi-
ture estimates were produced. Although such estimates
enable policymakers to understand the economic impact of
childhood asthma in the United States, it is necessary to
assess the per capita costs for children with asthma 
to determine the savings or benefits of a successful 
asthma intervention. 
Using the 1987 Medical Expenditure Panel Survey
(MEPS), a later study conducted by Lozano et al (6) esti-
mated the per capita health care costs for children with
asthma aged one to 17 years, including both asthma-relat-
ed expenditures only and all care expenditures (both asth-
ma and nonasthma care). For children with asthma aged
one to 17 years, the mean asthma-related per capita
expenditures totaled $171 per year; the mean all-care per
capita expenditures totaled $1129 ($468 for children with-
out asthma). However, those annual cost estimates were
based on parent-reported prevalence. Although 8.8% of the
study sample was classified as children with asthma (had
asthma or wheezing during the past 12 months), 56%
reported taking no asthma medication, and 12.3% report-
ed no health care use. To determine the reduction in
health costs that would result from an asthma interven-
tion, cost estimates based on treated prevalence or attack
prevalence are more appropriate than those using proxy-
reported prevalence. 
Beginning in 1997, the asthma questions on the NHIS
changed the measure of asthma prevalence (2). Now, three
measures are used, all restricted to persons with a medical
diagnosis of asthma. The first measure is referred to as
lifetime asthma prevalence, which includes respondents
with a medical diagnosis of asthma at any time in their
lives. The second measure identifies persons with a cur-
rent diagnosis of asthma. The third is a measure of 12-
month attack prevalence, which includes the number of
persons who had one or more attacks or episodes during
the past 12 months. 
The objective of this study is to estimate direct and indi-
rect costs of asthma among school-age children using data
from the 1996 MEPS. This study is different from previous
reports in four aspects: 1) it produces both national esti-
mates and per capita estimates; 2) the 1996 MEPS data
are used to derive not only medical cost estimates but also
SAD estimates; 3) both medical costs and SADs are esti-
mated based on treated prevalence; and 4) the costs of pro-
ductivity loss due to premature death among school-age
children are estimated. We hope that the results of this
study can provide more insights into the economic burden




A societal perspective was used to estimate costs of asth-
ma among school-age children. The direct costs of asthma
were estimated as asthma-related medical costs. Indirect
costs were estimated as costs of lost productivity, including
parents’ loss of productivity due to asthma-related SADs
and loss of productivity due to premature death of children
from asthma. Data from the 1996 MEPS were used to
derive medical cost and SAD estimates. Published esti-
mates were used for value of lost productivity (9), and data
from the National Vital Statistics System were used for
asthma mortality among school-age children (2). Both
national and per capita estimates were calculated. All
costs were in 2003 dollars.
Data source and data processing
The MEPS is the third in a series of national probabili-
ty surveys conducted by the Agency for Healthcare
Research and Quality (AHRQ) on the financing and use of
medical care in the United States. MEPS actually com-
prises a family of four surveys: 1) a household survey; 2)
a survey of medical providers; 3) a survey of health insur-
ance providers; and 4) a survey of nursing home residents.
Using the NHIS as its sampling frame, the MEPS house-
hold component (MEPS–HC) is designed to provide esti-
mates of health care use, spending, sources of payments,
and insurance coverage for the U.S. civilian noninstitu-
tional population. Using an overlapping panel design,
self-reports of health care use and spending are collected
at the person and household levels through five rounds of
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This yields two full years of data. The MEPS medical
provider component (MEPS–MPC) is a survey of medical
providers that are directly linked to the respondents in
the household survey. The MEPS–MPC is used to replace
or to supplement household data to reduce potential bias
from relying solely on self-reported data. The
MEPS–MPC focuses on medical events and collects infor-
mation on dates of visit, diagnosis and procedure codes,
and charges and payments. 
Although MEPS data are generally available from 1996
to 2000, we chose to use 1996 data for this study because
only 1996 data have information on SADs. The data used
in this article were derived from the 1996 Person-Level
Full-Year File (HC-012) and the Person-Level Medical
Event Files (HC-001). The 1996 MEPS–HC comprises a
sample of 10,597 households and 23,565 individuals.
Hispanic households were oversampled at ratios of
approximately 2:1; African American households were
oversampled at ratios of approximately 1.5:1. The sub-
sample of individuals used in this study consisted of all
children aged five to 17 years in 1996 and was further
divided into two condition groups: children with asthma
and children without asthma. In this study, the definition
of children with asthma was further refined to include
children who had any type of health care provider visit or
prescription medication related to asthma during the
year. All other children in the study sample were classi-
fied as children without asthma. We identified the chil-
dren with asthma through diagnosis code 493, according
to the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) (10). An event
cost associated with an ICD-9 code of 493 was considered
an asthma-related medical care cost and was derived
from the event files. Using the full-year file, we derived
estimates of all-cause medical spending and SADs for
each condition group. 
Expenditures in the 1996 MEPS are defined as the sum
of direct payments for care provided during the year,
including out-of-pocket payments and payments by pri-
vate insurance, Medicare, Medicaid, and other sources.
For this analysis, the medical events were classified and
enumerated into the following mutually exclusive cate-
gories: purchase of prescribed medicines, hospitalizations,
emergency room (ER) visits, outpatient hospital visits,
office-based visits, other medical equipments, and home
health care. 
To derive SAD estimates, we had to address two data
issues in the 1996 MEPS. First, Round 3 was conducted in
1996 and 1997; some data from Round 3 pertain to 1997.
The number of days lost from school in Round 3 that
occurred in each calendar year was not ascertained. We
developed an algorithm for deciding what portion of the
reported SADs occurred in 1996 (the number of days in
Round 3 in 1996 divided by the total number of days in
Round 3 and then multiplied by the total number of SADs
in Round 3). Second, two variables have missing data —
the ending date of Round 3 and SADs in Round 3 (34 chil-
dren with asthma and 583 children without asthma). We
used the SAS Multiple Imputation Procedure to impute
the missing values for the two variables (11).
Data analysis
The data were initially processed with SAS software
(SAS Institute, Inc, Cary, NC). All estimates produced in
this study were weighted to represent the U.S. population.
The sampling weights were used to adjust for potential
survey response bias. SUDAAN (Research Triangle
Institute, Research Triangle Park, NC) software was used
to account for the complex sample design in the computa-
tion of the final estimates and standard errors for the esti-
mates produced (12). Linear regression analyses were con-
ducted to estimate excess all-cause medical costs and
excess SADs for children with asthma compared with chil-
dren without asthma, controlling for the effects of sociode-
mographic and access-to-care variables such as age, sex,
race, mother’s education level, poverty status, and health
insurance coverage.
Calculation of direct and indirect costs
Asthma-related expenditures were considered as the
direct costs of asthma; estimates were directly derived
from MEPS data. The costs of parents’ loss of productivity
due to SADs were calculated as the product of SADs asso-
ciated with asthma and the cost of lost productivity (value
of a day lost). The costs of loss of productivity due to pre-
mature death were calculated as the product of asthma
mortality and the cost of lost productivity (discounted
value of future total earnings). 
According to a previous published study (9), the value of
a lost day was estimated to be $108 (in 2000 dollars) or
$115 (in 2003 dollars), which was calculated as the sum of
annual earnings and annual household services divided by
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365. The same study also reported the present value of
future total earnings (including fringe benefits) and of the
combination of future earnings and household production.
Estimates are reported at each exact age in five-year inter-
vals, beginning with birth. The reported estimates (in 2000
dollars and discounted at 3%) are $1,064,530 for a child
aged five years, $1,176,371 for a child aged 10, and
$1,290,814 for a child aged 15. In this study, we used the
average of the three estimates — $1,254,347 (in 2003 dol-
lars) — as the present value of future total earnings of chil-
dren who are currently aged five to 17 years.
A recent study by Akinbami and Schoendorf used data
from the Mortality Component of the National Vital
Statistics System and reported that annual asthma mor-
tality (per million) was 2.7 among children aged five to 10
years and 5.6 among children aged 11 to 17 years during
1995–1996 (2). We used these mortality estimates and the
1996 Census data to calculate the total asthma mortality
of children aged five to 17 years as 211. 
Results
As shown in Table 1, of a total of 4786 children aged five
to 17 years in our study sample, 248 had asthma-related
care during 1996, representing 2,521,537 children in the
United States. The annual treated prevalence rate of asth-
ma was 4.9%. Among all of the children with asthma in the
nation during 1996, 68% had at least one health care
provider visit of some type, and 94% purchased prescrip-
tions for asthma medication and devices. The percentage
of children with asthma who used asthma-related care by
category of service was 61% for office-based visits, 10% for
ER visits, 3% for outpatient visits, and 2% for hospitaliza-
tion. Sixty-five percent of children with asthma purchased
quick-relief medicine for asthma and 36% purchased con-
troller medicine for asthma. Asthma-related medical costs
were $1009.8 million ($401 per child) among all school-age
children with asthma in the nation. The distribution of
asthma-related expenditures shows that 43% of the total
expenditure was in prescribed medicine, followed by 36%
in outpatient and office-based visits and 21% in hospital-
ization and ER care.
Table 2 shows the all-cause medical care costs of chil-
dren with asthma and children without asthma. The all-
cause medical costs of children with asthma totaled $2590
million during 1996, with asthma-related care accounting
for 39% of the all-care costs. The weighted per capita costs
were $1042 for children with asthma and $618 for children
without asthma. Compared with a child without asthma, a
child with asthma had an excess of $424 in all-cause med-
ical spending. Comparing the cost distribution of children
with asthma to children without asthma, children with
asthma had a higher proportion of all-cause medical
expenditures in prescriptions, office-based visits, and out-
patient visits and a lower proportion of expenditures in
hospitalization and ER visits.
Table 3 shows the estimates of SADs in children with
and without asthma as well as excess SADs of children
with asthma compared with children without asthma.
Among 2.5 million school-age children with asthma, a total
of 14.5 million SADs occurred. On average, a child with
asthma missed 2.48 more days of school than a child with-
out asthma (5.81 SADs per child with asthma and 3.33
SADs per child without asthma). The total number of
SADs associated with asthma among all of the children
with asthma was 6.3 million, accounting for 43% of the
total SADs of all of the children with asthma for all illness
and injury. 
As shown in Table 4, the direct costs of asthma were esti-
mated to be $1009.8 million ($401 per child). The indirect
costs of asthma were estimated to be $983.8 million ($390
per child), including $719.1 million ($285 per child) 
associated with SADs and $264.7 million ($105 per child)
associated with premature deaths due to asthma. The
total economic impact of asthma in school-age children
was $1993.6 million ($791 per child). 
Discussion
This study is the first to produce both national and per
capita estimates of direct and indirect costs of children
with asthma. Although only 4.9% of U.S. children, or 2.5
million children nationally, had any type of health care
provider visit or prescription medication related to asthma
during 1996 (parent-reported asthma prevalence was
5.9%), the economic impact of asthma among those chil-
dren is substantial. The direct costs of asthma were esti-
mated to be $1009.8 million ($401 per child). The indirect
costs of asthma were estimated to be $983.8 million ($390
per child), including $719.1 million ($285 per child) 
associated with SADs and $264.7 million ($105 per child)
associated with premature deaths due to asthma. The
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was $1993.6 million ($791 per child).
Unlike most of the previous studies of childhood asthma,
this study focuses on children who had any treatment for
asthma during 1996. Before 1997, no other national sur-
vey collected information to measure treated prevalence or
attack prevalence. After the 1997 redesign of the NHIS
questionnaire, information to estimate asthma attack
prevalence was obtained. The 1996 treated prevalence of
asthma derived in this MEPS study (4.9%) is close to the
attack prevalence derived from the 1997 NHIS (5.9%
among children aged five to 10 years and 6.0% among chil-
dren aged 11 to 17 years). The annual prevalence of par-
ent-reported asthma in this MEPS study (5.9%) is in the
general range of other recent studies, where the preva-
lence of asthma in 1996 has been reported previously to be
5.5% among individuals aged five to 20 years (2), 7.4%
among children aged five to 10 years, and 7.7% among
children aged 11 to 17 years (2). 
Although two studies by Weiss et al (4,5) have previous-
ly estimated direct medical expenditures of asthma in chil-
dren, their estimates are not comparable to ours because
of two major differences. First, they used charges data,
which are very different from the payment data we used in
this study, to derive cost estimates. Second, they studied
costs for all children aged from birth to 17 years, rather
than for the school-age children we focused on in this
study. Although there is no comparable per capita esti-
mate in the literature to compare with our estimate of
asthma-related medical costs, we found that our per capi-
ta estimate of asthma-related costs ($401) is very close to
our estimate of the excess all-cause medical spending
($424) per child with asthma compared with a child 
without asthma. 
To our knowledge, this is the first study that uses MEPS
data to derive SAD estimates for children with asthma.
Most early SAD estimates were produced using NHIS
data. To compare the results of this MEPS study with
those of the most recent NHIS study, one should keep in
mind two differences between the studies. First, as noted
earlier, the definition of children with asthma is different.
In this study, only children who had treatment for asthma
were identified as children with asthma. In the NHIS
study, the definition of children with asthma was broader:
children with asthma did not have to have treatment if
their parents believed that they had asthma during the
year. Second, the information collected on SADs is differ-
ent between the two data sets. Although the 1996 MEPS
obtained information on the total number of SADs for each
child and on the conditions that caused the SADs, it col-
lected no information on the number of SADs associated
with a particular condition. Thus, our SAD estimates
reflect annual SADs resulting from all conditions. In con-
trast, the NHIS provided data on the number of SADs
resulting from specific conditions (i.e., SADs associated
with asthma). Based on the MEPS data, we found that the
total number of SADs in 1996 resulting from all conditions
was 14.5 million among children with treated asthma
(5.75 days per child). On average, a child with asthma had
an excess of 2.5 SADs compared with a child without asth-
ma. The study using 1994–1996 NHIS data found that the
annual number of SADs associated with asthma was 14
million (3.7 days per child) among children with 
parent-reported asthma. Although our SAD estimates are
different from those of the NHIS study, we found that the
proportion of all children with asthma who had asthma-
related SADs (49%) is interestingly close to the proportion
of all SADs associated with asthma at the individual level
(42% = 2.48/5.81). This indicates internal consistency in
the MEPS data. 
Like many other cost analyses, this study has some clear
limitations. The results of this study should be interpreted
with some degree of caution. First, as noted earlier, the
medical condition data in the MEPS were derived from
parents’ reports; they may not conform perfectly to diag-
noses made by physicians. However, a study by AHRQ
staff indicated that, at the three-digit ICD-9 code level,
there was agreement between household- and provider-
reported conditions in the overwhelming majority of cases
(13). In addition, this concern is minimized by the fact that
most of the children (94%) who were classified as children
with asthma in this study had purchased prescription
medicine for asthma. Second, in the MEPS event data file,
a health service may occur for multiple reasons; spending
associated with specific conditions is not mutually exclu-
sive. However, in this study, we also estimated all medical
spending for children with asthma and compared them
with children without asthma. Because the estimated per
capita asthma-related cost ($401) is very close to the esti-
mated excess cost per child with asthma ($424), it is rea-
sonable to believe that our direct cost estimates are fairly
accurate. Third, we did not use asthma medication data as
a means of identifying children with asthma; we might
have underestimated the treated prevalence as well as the
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national medical expenditure of children with asthma.
There were more probable asthma cases in the 1996
MEPS data. Among children who had neither proxy-
reported asthma nor treated asthma in the study sample,
15 probably really had asthma because they purchased
albuterol more than once during a year. Fourth, we have
significantly underestimated the direct costs of asthma in
school-age children, because children with asthma receive
a substantial proportion of care in school settings. Because
MEPS is limited to expenditures in medical settings, the
cost of services provided by the school system, such as
nursing care and first-aid care provided by school nurses,
school health aids, and school secretaries, were not includ-
ed in this study. Fifth, the sample size for inpatient, out-
patient, and emergency care was small. However, the
focus of this study was total medical expenditures across
all medical care services, for which we had a sufficient
sample size to be confident in both national estimates and
per capita estimates. 
Even with these limitations, it is reasonable to conclude
that the economic impact of asthma to school-age children,
families, and society is immense, and more public health
efforts are needed to better control asthma in children.
Evidence from evaluation studies of asthma intervention
programs suggest that asthma among school-age children
can be controlled, and significant cost savings in medical
care and parents’ loss of productivity from asthma-related
SADs can be realized, especially when the programs are
aimed at children with moderate to severe asthma (14-21).
Two economic studies of clinical-based asthma education
programs have documented cost savings from $180 per
enrolled child with at least persistent asthma to $542 per
enrolled child with a history of frequent use of ER services
for asthma (14,15). One particularly well-designed ran-
domized controlled trial of an inner-city social-
worker–based education program was able to demonstrate
cost savings of $2509 per child with one or more hospital
visits at baseline, $1050 per child with two or more
unscheduled visits at baseline, and $220 per child with
more than 50% of days with asthma symptoms (16). Two
studies of asthma management programs found a cost sav-
ings of $1144 per inpatient child as a result of an inpatient
asthma clinical pathway and a cost savings of $1667 per
child with one or more hospitalizations or two or more ER
visits during a six-month period as a result of a home-
based self-management program (17,18). Studies examin-
ing the impact of asthma interventions on SADs have also
found significant reduction in SADs, including a 1.8-day
reduction by a school-based asthma education program, a
two-day reduction by a summer asthma camp-based edu-
cation program for children with moderate to severe asth-
ma, and a 2.5-day reduction by a large-scale population-
based asthma management program for asthma patients
and their caregivers (19-21). 
Based on the medical cost estimates derived in this
study, we found that $211.4 million in medical 
expenditures (21% of the total asthma-related medical
expenditures in 1996) are preventable with effective asth-
ma interventions, including $120.8 million in inpatient
care and $90.6 million in ER care. In addition, published
asthma intervention studies reveal that SADs related to
asthma can be reduced by 1.8 to 2.5 days (19-21). Since the
cost estimate of parents’ loss of productivity derived in this
study was based on an additional 2.5 SADs per child with
asthma relative to a child without asthma, it is reasonable
to believe that more than half of the total indirect costs of
parent’s loss of productivity ($983.8 million) are preventa-
ble with effective interventions. However, to achieve such
cost savings, more public health efforts are needed to 
educate parents and children on the child’s condition and
medications, the need for follow-up care, and the impor-
tance of avoiding known disease triggers. To ensure the
success of such effort, education of primary care providers
and school staff and efficient collaboration among primary
care providers, school health professionals, and health
education professionals are essential. 
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Tables
Table 1. Asthma-related Medical Care Among U.S. Children Aged Five to 17 Yearsa
Table 2. Comparison of All-cause Medical Expenditures of U.S. Children Aged Five to 17 Years With and Without Asthmaa
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aBased on sample size of 4786. Source: 1996 Medical Expenditure Panel Survey. SE = standard error. NA = not applicable. 
bExpenditures are presented in 2003 dollars.
Prescription 263 651,578,798  25  146  3,525,325,923  11 
(25) (78,265,297)  (21)  (510,679,902)   
Inpatient 3328 284,511,726  11  9254  9,657,060,475  29 
(819) (134,082,066)  (1999)  (2,439,668,298)   
Outpatient 898 260,576,661  10  1068  3,110,152,939  9 
(271) (93,150,742) (189)  (598,533,120) 
Emergency 364 199,370,182  8  677  3,765,138,136  11 
(51) (42,482,913) (170)  (974,320,040) 
Number of persons Expendituresb
% of children  Per capita Weighted
who used weighted Weighted expenditure
each  service  expenditure, expenditure, distribution,
Medical care Un-weighted Weighted (weighted) $ (SE) $ (SE) %
Prescription 230 2,375,040 94 183 433,761,955 43
(20) (58,520,972)
Inpatient 5 55,072 2 2193 120,768,739 12
(337) (81,768,373)
Outpatient 8 76,413 3 635 48,481,437 5
(377) (35,537,654)
Emergency 24 244,170 10 371 90,592,184 9
(89) (31,553,044)
Office visit 153 1,532,728 61 206 316,158,833 31
(47) (78,720,894)
Total 248 2,521,537 NA 401 1,009,763,148 100
(54) (147,630,859)
(Continued on next page)
Children with asthma  Children without asthma 
(N = 2,521,537)  (N = 49,084,023) 
Per capita  National  Expenditure  Per capita  National  Expenditure 
expenditure, expenditure,  distribution,  expenditure,  expenditure,  distribution, 
Medical care  $ (SE)  $ (SE)  %  $ (SE)  $ (SE)  % VOLUME 2: NO. 1
JANUARY 2005
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Table 2. (continued) Comparison of All-cause Medical Expenditures of U.S. Children Aged Five to 17 Years With and Without
Asthmaa
Children with asthma  Children without asthma 
(N = 2,521,537)  (N = 49,084,023) 
Per capita  National  Expenditure  Per capita  National  Expenditure 
expenditure, expenditure,  distribution,  expenditure,  expenditure,  distribution, 
Medical care  $ (SE)  $ (SE)  %  $ (SE)  $ (SE)  % 
Office visit  435 954,241,953  37  327  10,774,764,219  33 
(66) (152,081,219) (17)  (687,815,760) 
Other equipment 558 239,714,979  9  231  1,538,558,287  5 
(372) (157,341,673) (18)  (158,934,373) 
Home visit  0 0  0  2762  714,950,437  2 
(1365) (365,042,774) 
Total expenditure 1027 2,589,994,298  100  675  33,085,950,417  100 
(110) (317,235,615) (72)  (3,598,962,584) 
Adjusted per capita 1042 NA  NA  618 NA  NA 
expenditureb (112) (62) 
aSource: 1996 Medical Expenditure Panel Survey. All expenditures are weighted and in 2003 dollars. SE = standard error. NA = not applicable.
bAdjusted by age, sex, race, mother’s eduction level, poverty status, and health insurance coverage.
Table 3. Estimates of School Absence Days (SADs) Among U.S. Children Aged Five to 17 Years With and Without Asthmaa
aData are from 1996 Medical Expenditure Panel Survey. All values are numbers (standard errors) unless otherwise indicated. NA = not applicable.
bAdjusted by age, sex, race, mother's education level, poverty status, and health insurance coverage.
Total SAD  1440 14,489,164 15,454 166,321,913  NA 
(1,448,744) (6,935,832) 
SAD per child  5.8 5.75  3.41  3.39 2.36 
(0.41) (0.12) 
Adjusted SAD per  NA 5.81  NA  3.33 2.48 
childb (0.40) (0.12) 
Children with asthma  Children without asthma  Excess SADs per 
child with asthma
Unweighted  Weighted  Unweighted  Weighted  compared with a child 
(n = 248)  (n = 2,521,537)  (n = 4538)  (n = 49,084,023)  without asthmaVOLUME 2: NO. 1
JANUARY 2005
Table 4. Direct and Indirect Costs of Asthma Among U.S. Children Aged Five to 17 Years (in 2003 Dollars)
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National estimate 1,009,763,148 719,142,352  264,667,217  1,993,572,717 
Per capita estimate 401 285  105 791 
Direct costs ($)  Indirect costs ($)  Total costs ($) 
Asthma-related Costs of lost productivity due to Costs of lost productivity 
medical costs  asthma-related school absence days   due to premature death